Cardio Diagnostics Holdings, Inc. (CDIO) 10-Year Financial Performance & Capital Metrics

CDIO • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesDiagnostics & Immune Monitoring

AboutCardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.Show more

Revenue $35K +104.5%
EBITDA -$8M -13.4%
Net Income -$8M
EPS (Diluted) -9.30 +53.0%
Gross Margin 100%
EBITDA Margin -23185.82% +44.5%
Operating Margin -23977.86% +43.5%
Net Margin -24028.24% +51.1%
ROE -133.96% +41.9%
ROIC -222.66% +18.7%
Debt/Equity 0.10 -76.2%
Interest Coverage -448.81 -41636.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 3 (bottom 3%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y238.32%

TTM-55.78%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM20.61%

EPS CAGR

10Y-

5Y-

3Y-

TTM-40.17%

ROCE

10Y Avg-318.86%

5Y Avg-318.86%

3Y Avg-158.4%

Latest-122.98%

Peer Comparison

Diagnostics & Immune Monitoring

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TECHBio-Techne Corporation	10.9B	69.96	152.09	5.23%	6.41%	3.97%	2.35%	0.23
SPRYARS Pharmaceuticals, Inc.	1.1B	11.09	142.00	2970.63%	-56.06%	-54.21%	1.18%	0.00
VCYTVeracyte, Inc.	3.24B	41.00	132.26	23.46%	6.12%	2.41%	1.97%	0.04
CSBRChampions Oncology, Inc.	99.56M	7.17	21.73	13.54%	4.32%	59.65%	7.03%	1.62
MDXGMiMedx Group, Inc.	851.59M	5.75	20.54	8.52%	10.38%	17.09%	7.58%	0.13
LTRNLantern Pharma Inc.	39.26M	3.51	-0.00			-197.36%		0.01
SEERSeer, Inc.	107.44M	1.91	-1.37	-8.13%	-486.02%	-29.19%		0.08
IMDXInsight Molecular Diagnostics Inc.	189.76M	6.62	-1.42	25.15%	-13.81%	-14.81%

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	901	950	17.07K	34.89K
Revenue Growth %	-	-	0.05%	16.96%	1.04%
Cost of Goods Sold+	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-
Gross Profit+	0	901	950	17.07K	34.89K
Gross Margin %	-	1%	1%	1%	1%
Gross Profit Growth %	-	-	0.05%	16.96%	1.04%
Operating Expenses+	609.16K	621.35K	4.55M	7.26M	8.4M
OpEx % of Revenue	-	689.62%	4788.84%	425.4%	240.78%
Selling, General & Admin	597K	573.88K	4.49M	7.1M	8.35M
SG&A % of Revenue	-	636.94%	4729.42%	415.77%	239.38%
Research & Development	1.5K	31.47K	40.45K	145.18K	29.13K
R&D % of Revenue	-	34.93%	42.58%	8.51%	0.83%
Other Operating Expenses	10.67K	16K	16K	19.18K	19.74K
Operating Income+	-609.16K	-620.45K	-4.55M	-7.24M	-8.37M
Operating Margin %	-	-688.62%	-4787.84%	-424.4%	-239.78%
Operating Income Growth %	-	-0.02%	-6.33%	-0.59%	-0.16%
EBITDA+	-598.5K	-604.45K	-4.53M	-7.13M	-8.09M
EBITDA Margin %	-	-670.86%	-4771%	-417.86%	-231.86%
EBITDA Growth %	-	-0.01%	-6.5%	-0.57%	-0.13%
D&A (Non-Cash Add-back)	10.67K	16K	16K	111.62K	276.35K
EBIT	-609.16K	-620.45K	-4.66M	-1.64M	-8.36M
Net Interest Income+	0	0	0	-6.73M	-17.58K
Interest Income	0	0	0	1.07K	1.06K
Interest Expense	0	0	0	6.74M	18.64K
Other Income/Expense	4K	0	-112.53K	-1.13M	-17.58K
Pretax Income+	-605.16K	-620.45K	-4.66M	-8.38M	-8.38M
Pretax Margin %	-	-688.62%	-4906.3%	-490.88%	-240.28%
Income Tax+	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%
Net Income+	-605.16K	-620.45K	-4.66M	-8.38M	-8.38M
Net Margin %	-	-688.62%	-4906.3%	-490.88%	-240.28%
Net Income Growth %	-	-0.03%	-6.51%	-0.8%	-0%
Net Income (Continuing)	-605.16K	-620.45K	-4.66M	-8.38M	-8.38M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-0.06	-1.96	-45.30	-19.80	-9.30
EPS Growth %	-	-29.82%	-22.11%	0.56%	0.53%
EPS (Basic)	-0.06	-1.96	-45.30	-19.80	-9.30
Diluted Shares Outstanding	9.52M	317.16K	3.09M	422.84K	26.89M
Basic Shares Outstanding	9.52M	317.16K	3.09M	422.84K	26.89M
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	245.92K	803.51K	5.89M	2.77M	8.79M
Cash & Short-Term Investments	237.09K	512.77K	4.12M	1.28M	7.83M
Cash Only	237.09K	512.77K	4.12M	1.28M	7.83M
Short-Term Investments	0	0	0	0	0
Accounts Receivable	0	901	0	4.96K	18.61K
Days Sales Outstanding	-	365	-	106.09	194.71
Inventory	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-
Other Current Assets	0	250K	0	1.48M	621.32K
Total Non-Current Assets+	200.46K	298.49K	363.59K	1.7M	1.82M
Property, Plant & Equipment	0	0	0	1.15M	1.11M
Fixed Asset Turnover	-	-	-	0.01x	0.03x
Goodwill	0	0	0	0	0
Intangible Assets	200.46K	298.49K	358.64K	536.74K	706.42K
Long-Term Investments	0	0	0	0	0
Other Non-Current Assets	0	0	4.95K	12.85K	12.85K
Total Assets+	446.38K	1.1M	6.25M	4.46M	10.62M
Asset Turnover	-	0.00x	0.00x	0.00x	0.00x
Asset Growth %	-	1.47%	4.67%	-0.29%	1.38%
Total Current Liabilities+	386.01K	33.88K	1.95M	841.14K	631.7K
Accounts Payable	39.54K	33.88K	1.1M	243.21K	87.66K
Days Payables Outstanding	-	-	-	-	-
Short-Term Debt	0	0	849.03K	374K	306.76K
Deferred Revenue (Current)	0	0	0	0	0
Other Current Liabilities	346.47K	0	0	0	0
Current Ratio	0.64x	23.71x	3.02x	3.29x	13.92x
Quick Ratio	0.64x	23.71x	3.02x	3.29x	13.92x
Cash Conversion Cycle	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	663.1K	425.83K
Long-Term Debt	0	0	0	0	0
Capital Lease Obligations	0	0	0	663.1K	425.83K
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0
Total Liabilities	386.01K	33.88K	1.95M	1.5M	1.06M
Total Debt+	0	0	849.03K	1.26M	969.86K
Net Debt	-237.09K	-512.77K	-3.27M	-22.5K	-6.86M
Debt / Equity	-	-	0.20x	0.43x	0.10x
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-	-	-	-1.08x	-448.81x
Total Equity+	60.37K	1.07M	4.3M	2.96M	9.56M
Equity Growth %	-	16.69%	3.03%	-0.31%	2.23%
Book Value per Share	0.01	3.37	1.39	7.00	0.36
Total Shareholders' Equity	60.37K	1.07M	4.3M	2.96M	9.56M
Common Stock	1.05K	123	95	205	459
Retained Earnings	-710.11K	-1.33M	-5.99M	-14.37M	-22.75M
Treasury Stock	0	0	0	0	0
Accumulated OCI	0	0	0	0	0
Minority Interest	0	0	0	0	0

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	25.86K	-585.29K	-5.09M	-5.67M	-4.99M
Operating CF Margin %	-	-649.6%	-5358.91%	-332.39%	-143.11%
Operating CF Growth %	-	-23.63%	-7.7%	-0.11%	0.12%
Net Income	-605.16K	-620.45K	-4.66M	-8.38M	-8.38M
Depreciation & Amortization	10.67K	16K	16K	111.62K	276.35K
Stock-Based Compensation	589.26K	60K	0	1.28M	2.59M
Deferred Taxes	0	0	0	0	0
Other Non-Cash Items	0	-3.28K	112.53K	1.1M	0
Working Capital Changes	31.09K	-37.56K	-558.52K	208.81K	522.84K
Change in Receivables	0	-901	0	-4.96K	-13.65K
Change in Inventory	0	0	0	0	0
Change in Payables	0	0	136.35K	0	0
Cash from Investing+	-29.91K	-364.03K	-368K	-794.29K	-404.19K
Capital Expenditures	-29.91K	-114.03K	-76.15K	-597.01K	-214.76K
CapEx % of Revenue	-	126.56%	80.16%	34.98%	6.16%
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	0	0	-433.33K	-197.28K	-189.43K
Cash from Financing+	240K	1.23M	9.06M	3.63M	11.94M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	240K	105K	-2.73M	-867.53K	-605.69K
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-4.05K	-699.32K	-5.09M	-6.47M	-5.4M
FCF Margin %	-	-776.16%	-5358.92%	-378.93%	-154.69%
FCF Growth %	-	-171.63%	-6.28%	-0.27%	0.17%
FCF per Share	-0.00	-2.20	-1.65	-15.29	-0.20
FCF Conversion (FCF/Net Income)	-0.04x	0.94x	1.09x	0.68x	0.60x
Interest Paid	0	0	0	30.49K	18.64K
Taxes Paid	0	0	0	0	0

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-1002.51%	-109.96%	-173.6%	-230.77%	-133.96%
Return on Invested Capital (ROIC)	-	-245.81%	-429.49%	-273.72%	-222.66%
Gross Margin	-	100%	100%	100%	100%
Net Margin	-	-68862.15%	-490630%	-49087.81%	-24028.24%
Debt / Equity	-	-	0.20x	0.43x	0.10x
Interest Coverage	-	-	-	-1.08x	-448.81x
FCF Conversion	-0.04x	0.94x	1.09x	0.68x	0.60x
Revenue Growth	-	-	5.44%	1696.32%	104.45%

Frequently Asked Questions

Growth & Financials

Cardio Diagnostics Holdings, Inc. (CDIO) reported $0.0M in revenue for fiscal year 2024.

Cardio Diagnostics Holdings, Inc. (CDIO) grew revenue by 104.5% over the past year. This is strong growth.

Cardio Diagnostics Holdings, Inc. (CDIO) reported a net loss of $6.6M for fiscal year 2024.

Dividend & Returns

Cardio Diagnostics Holdings, Inc. (CDIO) has a return on equity (ROE) of -134.0%. Negative ROE indicates the company is unprofitable.

Cardio Diagnostics Holdings, Inc. (CDIO) had negative free cash flow of $6.0M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener